Using immunohistochemistry, we examined a large cohort of 135 ovarian tumors, made up of 96 low-grade serous carcinomas (LGSCs) and 39 serous borderline tumors (micropapillary variant, mSBT), with the aim of exploring their HER2 status (overexpression). We followed with comprehensive genomic analyses on this sample set from our previous study, which revealed HER2 mutation in 5% (4/75) of LGSC and 10% (3/29) of mSBT. No cases were evaluated as HER2-positive, but 6 LGSCs and 1 mSBT were scored as HER2 1+, and 2 LGSCs and 1 mSBT showed the so-called HER2 "ultra-low" phenotype. This could be of clinical value as a potential therapeutical target concerning emerging therapeutic treatments (antibody conjugates). However, the clinical significance of this expression still needs to be established.

Department of Oncological Pathology Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Pathology and Molecular Medicine 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University Thomayer University Hospital Prague Czech Republic

Department of Pathology Charles University 3rd Faculty of Medicine University Hospital Královské Vinohrady Prague Czech Republic

Department of Pathology Faculty of Medicine University of Debrecen Debrecen Hungary

The Fingerland Department of Pathology Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové Czech Republic

Zobrazit více v PubMed

Seidman JD, Ronnett BM, Shih I-M, et al. Epithelial Tumors of the Ovary. In: Kurman RJ. Blaustein’s pathology of the female genital tract 2019. New York: Springer, 842–951.

McCluggage WG, LAX SF, Soslow RA, et al. Tumours of the ovary. In: WHO Classification of Tumours Editorial Board. Female genital tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 4). Accessed February 25, 2024. https://tumourclassification.iarc.who.int/chapters/34

Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006;108:361–368.

Ahn G, Folkins AK, McKenney JK, et al. Low-grade Serous carcinoma of the ovary: clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion. Am J Surg Pathol 2016;40:1165–1176.

Cheasley D, Nigam A, Zethoven M, et al. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J Pathol 2021;253:41–54.

Chuang J, Klempner S, Waters K, et al. Therapeutic Advances and challenges in the management of HER2-positive gastroesophageal cancers. Diseases 2022;10:23.

Kavuri SM, Jain N, Galimi F, et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 2015;5:832–841.

Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382:610–621.

Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 2020;26:3928–3935.

Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 2018;36:2044–2051.

Lassus H, Leminen A, Vayrynen A, et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004;92:31–39.

Wu Y, Soslow RA, Marshall DS, et al. Her-2/neu expression and amplification in early-stage ovarian surface epithelial neoplasms. Gynecol Oncol 2004;95:570–575.

Mayr D, Kanitz V, Amann G, et al. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 2006;48:149–156.

Mohammed RAA, Makboul R, Elsers DAH, et al. Pattern of HER-2 gene amplification and protein expression in benign, borderline, and malignant ovarian serous and mucinous neoplasms. Int J Gynecol Pathol 2017;36:50–57.

Chakravarty D, Gao J, Phillips S, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol 2017;2017:1–16.

Anglesio MS, Arnold JM, George J, et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008;6:1678–1690.

Hunter SM, Anglesio MS, Ryland GL, et al. Molecular profiling of low-grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 2015;6:37663–37677.

Zhang X, Devins K, Ko EM, et al. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-clinical significance of BRCA2 gene variants in genomically stable tumors. Gynecol Oncol 2021;161:762–768.

Ishibashi T, Nakayama K, Razia S, et al. High frequency of PIK3CA mutations in low-grade serous ovarian carcinomas of Japanese patients. Diagnostics (Basel) 2019;10:13.

Stružinská I, Hájková N, Hojný J, et al. Somatic genomic and transcriptomic characterization of primary ovarian serous borderline tumors and low-grade serous carcinomas. J Mol Diagn 2024;26:257–266.

Dundr P, Bazalova B, Bartu M, et al. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. Virchows Arch 2022;481:201–212.

Nemejcova K, Bartu MK, Michalkova R, et al. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors. Diagn Pathol 2023;18:15.

Nemejcova K, Safanda A, Bartu MK, et al. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors. Diagn Pathol 2023;18:32.

Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical practice guideline focused update. J Clin Oncol 2018;36:2105–2122.

Kendall Bartu M, Nemejcova K, Michalkova R, et al. HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma. Virchows Arch 2023;483:497–507.

Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 2021;22:1151–1161.

Shin JW, Kim S, Ha S, et al. The HER2 S310F mutant can form an active heterodimer with the EGFR, which can be inhibited by cetuximab but not by trastuzumab as well as pertuzumab. Biomolecules 2019;9:629.

Sanders BE, Ku L, Walker P, et al. Assessing genetic variants in matched biocompartments from patients with serous ovarian cancer. Technol Cancer Res Treat 2021;20:15330338211027917.

Xu B, Amallraja A, Swaminathan P, et al. Case report: 16-yr life history and genomic evolution of an ER(+) HER2(-) breast cancer. Cold Spring Harb Mol Case Stud 2020;6:a005629.

Jiao XD, Liu K, Wu Y, et al. HER2 splice site mutation c.1899-1G>A as the potential acquired resistance to trastuzumab in a patient with HER2-positive gastric adenocarcinoma. Oncologist 2021;26:717–721.

Tuefferd M, Couturier J, Penault-Llorca F, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2007;2:e1138.

O’Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005;29:1034–1041.

Wu D, Lei Y, Liu Q, et al. Characterization and clinical significance of the CADM1/HER2/STAT3 axis in serous ovarian tumors. Medicine (Baltimore) 2021;100:e23777.